Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Therapeutics: Ephrin B2 (EFNB2); zinc finger E-box binding homeobox 2 (ZEB2)

Cancer

INDICATION: Brain cancer

Patient sample and mouse studies suggest inhibiting ZEB2, a negative regulator of EFNB2, could help

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE